RecruitingNCT03869619

REal World Data in LYmphoma and Survival in Adults

REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS

Sponsor

Hospices Civils de Lyon

Enrollment

6,000 participants

Start Date

Nov 14, 2018

Study Type

OBSERVATIONAL

Conditions

Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Diffuse Large B Lymphoma (DLBCL)T-cell Lymphoma (T-NHL)Hodgkin's Lymphoma (HL)Burkitt Lymphoma (BL))

Summary

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to * Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a large patient registry study tracking real-world outcomes for adults newly diagnosed with lymphoma. Researchers want to understand how different types of lymphoma behave and how patients respond to treatments in everyday clinical settings — not just in controlled trials. Data collected will help improve future care. **You may be eligible if...** - You are 18 years or older - You have been recently diagnosed with lymphoma within the last 6 months - Your lymphoma is one of these types: diffuse large B-cell, follicular, mantle cell, marginal zone, T-cell, Hodgkin's, or Burkitt lymphoma - You are willing to sign the consent form for the REALYSA cohort **You may NOT be eligible if...** - You have already started anti-lymphoma treatment (other than a brief pre-treatment with steroids or similar) - You have documented HIV infection - Your lymphoma type is not on the eligible list (for example, chronic lymphocytic leukemia or hairy cell leukemia) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERReal-life epidemiological platform of lymphoma in France

The REALYSA database will be described with the following characteristics: * Number of patients included per month in total and according to subtype of lymphoma * Number of patients in each region in total and according to subtype of lymphoma

Locations(37)

Unité d'Hématologie Clinique, CH D'ARRAS

Arras, France

Service d'Hématologie, CHU Jean Minjoz

Besançon, France

Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine

Bordeaux, France

Institut Bergonié

Bordeaux, France

Centre Hospitalier Pierre Oudot

Bourgoin, France

Service d'Hématologie, Institut d'Hématologie de Basse Normandie

Caen, France

METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,

Chambéry, France

Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand

Clermont-Ferrand, France

Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor

Créteil, France

CHU Francois MITTERRAND

Dijon, France

Service Hématologie, Centre Hospitalier de Dunkerque

Dunkirk, France

Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,

Grenoble, France

CHD Vendée

La Roche-sur-Yon, France

Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon

La Tronche, France

Clinique Victor Hugo

Le Mans, France

Centre hospitalier Libourne

Libourne, France

Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL

Lille, France

Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille

Lille, France

Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,

Limoges, France

Département d'Hématologie et Oncologie, Centre Léon Bérard

Lyon, France

Département d'Hématologie Clinique, Hôpital Saint-Eloi,

Montpellier, France

Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,

Mulhouse, France

Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes

Nantes, France

Centre Hospitalier de Niort

Niort, France

Service Hématologie, Hôpital St Louis

Paris, France

CHU Haut-Lévêque

Pessac, France

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers

Poitiers, France

Hématologie Clinique, CHU PONTCHAILLOU

Rennes, France

Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo

Roubaix, France

Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL

Rouen, France

Service Hématologie, CH YVES LE FOLL

Saint-Brieuc, France

Service Hématologie, Institut Curie - Hôpital René HUGUENIN

Saint-Cloud, France

Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, France

Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Institut Universitaire du Cancer

Toulouse, France

Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE

Vannes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03869619

Related Trials

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT0346097782 locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744266 locations

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT072499052 locations

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

NCT075486971 location

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT0513102262 locations